LTPA2016047I1 - Timidinkinazė - Google Patents

Timidinkinazė

Info

Publication number
LTPA2016047I1
LTPA2016047I1 LTPA2016047C LTPA2016047C LTPA2016047I1 LT PA2016047 I1 LTPA2016047 I1 LT PA2016047I1 LT PA2016047 C LTPA2016047 C LT PA2016047C LT PA2016047 C LTPA2016047 C LT PA2016047C LT PA2016047 I1 LTPA2016047 I1 LT PA2016047I1
Authority
LT
Lithuania
Prior art keywords
kinase
timidin
nucleotides
splice
polynucleotide
Prior art date
Application number
LTPA2016047C
Other languages
English (en)
Original Assignee
Molmed Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Molmed Spa filed Critical Molmed Spa
Publication of LTPA2016047I1 publication Critical patent/LTPA2016047I1/lt
Publication of LTC1781789I2 publication Critical patent/LTC1781789I2/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • C12N9/1211—Thymidine kinase (2.7.1.21)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
LTPA2016047C 2004-06-18 2016-12-28 Timidinkinazė LTC1781789I2 (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0413702.2A GB0413702D0 (en) 2004-06-18 2004-06-18 Thymidine kinase
PCT/IB2005/002358 WO2005123912A2 (en) 2004-06-18 2005-06-17 Thymidine kinase

Publications (2)

Publication Number Publication Date
LTPA2016047I1 true LTPA2016047I1 (lt) 2017-01-25
LTC1781789I2 LTC1781789I2 (lt) 2018-10-10

Family

ID=32750189

Family Applications (1)

Application Number Title Priority Date Filing Date
LTPA2016047C LTC1781789I2 (lt) 2004-06-18 2016-12-28 Timidinkinazė

Country Status (21)

Country Link
US (5) US8357788B2 (lt)
EP (1) EP1781789B1 (lt)
JP (1) JP5091669B2 (lt)
KR (1) KR101337210B1 (lt)
CN (1) CN101010428B (lt)
AT (1) ATE520779T1 (lt)
AU (1) AU2005254807B2 (lt)
CA (1) CA2569304C (lt)
CY (2) CY1111925T1 (lt)
DK (1) DK1781789T3 (lt)
ES (1) ES2372022T3 (lt)
GB (1) GB0413702D0 (lt)
HK (1) HK1097881A1 (lt)
HU (1) HUS1600064I1 (lt)
IL (2) IL179660A (lt)
LT (1) LTC1781789I2 (lt)
NL (1) NL300856I2 (lt)
PL (1) PL1781789T3 (lt)
PT (1) PT1781789E (lt)
SI (1) SI1781789T1 (lt)
WO (1) WO2005123912A2 (lt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0413702D0 (en) 2004-06-18 2004-07-21 Molmed Spa Thymidine kinase
CA2848939A1 (en) 2011-10-05 2013-04-11 Molmed Spa Viral vectors purification system
WO2019132596A1 (ko) 2017-12-28 2019-07-04 주식회사 바이오녹스 안전성 및 항암효과가 개선된 종양 용해 바이러스
US11157042B1 (en) 2018-03-28 2021-10-26 Douglas Patton Systems and methods for interaction of wearable communication devices
EP3802796A1 (en) 2018-05-30 2021-04-14 Glycostem Therapeutics B.V. Car nk cells
CN114096661A (zh) * 2019-06-27 2022-02-25 拜耳诺克斯有限公司 改进了安全性及抗肿瘤效果的溶瘤病毒

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0454781B1 (en) 1989-01-23 1998-12-16 Chiron Corporation Recombinant cells for therapies of infection and hyperproliferative disorders and preparation thereof
DE69032841T2 (de) 1989-01-23 1999-05-12 Chiron Corp Rekombinante zellen für therapien von infektionen und hyperprolieferative störungen und deren herstellung
US5631236A (en) 1993-08-26 1997-05-20 Baylor College Of Medicine Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk
IT1261847B (it) 1993-09-01 1996-06-03 San Romanello Centro Fond Metodo per marcare cellule eucariote.
FR2712603B1 (fr) 1993-11-18 1996-02-09 Centre Nat Rech Scient Virus recombinants, préparation et utilisation en thérapie génique.
EP0758387B1 (en) 1994-05-02 2001-12-19 University of Washington Thymidine kinase mutants
US6207150B1 (en) * 1996-02-09 2001-03-27 Aventis Pharma S.A. Variants of thymidine kinase, nucleic acids encoding them, and methods of using them
FR2751988B1 (fr) 1996-08-01 1998-09-11 Rhone Poulenc Rorer Sa Nouveaux variants de la thymidine kinase, sequences d'acides nucleiques correspondantes et leur utilisation en therapie genique
FR2744731B1 (fr) 1996-02-09 1998-05-22 Rhone Poulenc Rorer Sa Nouveaux variants de la thymidine kinase, sequences d'acides nucleiques correspondantes et leur utilisation en therapie genique
CA2251078A1 (en) 1996-04-10 1997-10-16 The University Of Southern California Gene therapy for proliferative vitreoretinopathy
EP1886677A1 (en) 1996-07-26 2008-02-13 Susan P. Perrine Use of an inducing agent for the treatment of blood, viral and cellular disorders
ATE374247T1 (de) 1997-10-14 2007-10-15 Darwin Molecular Corp Thymidinkinase mutanten und fusionproteine mit thymidinkinase und guanylatekinase aktivitäten
GB0008966D0 (en) * 2000-04-13 2000-05-31 Imp College Innovations Ltd Vectors for gene therapy
CN1273587C (zh) * 2002-06-05 2006-09-06 上海新世界基因技术开发有限公司 疱疹病毒胸苷激酶突变体及其应用
DE50213745D1 (de) * 2002-12-09 2009-09-17 Celltech Gmbh Biotechnologie Verbesserte retrovirale Vektoren für die Gentherapie
GB0413702D0 (en) 2004-06-18 2004-07-21 Molmed Spa Thymidine kinase

Also Published As

Publication number Publication date
JP2008502342A (ja) 2008-01-31
ATE520779T1 (de) 2011-09-15
CY1111925T1 (el) 2015-11-04
SI1781789T1 (sl) 2012-03-30
IL213084A0 (en) 2011-07-31
AU2005254807A1 (en) 2005-12-29
HK1097881A1 (en) 2007-07-06
US10314925B2 (en) 2019-06-11
PT1781789E (pt) 2011-10-20
US20140178345A1 (en) 2014-06-26
DK1781789T3 (da) 2011-11-28
CA2569304A1 (en) 2005-12-29
CN101010428B (zh) 2013-10-02
AU2005254807B2 (en) 2011-08-18
WO2005123912A2 (en) 2005-12-29
ES2372022T3 (es) 2012-01-13
JP5091669B2 (ja) 2012-12-05
US8357788B2 (en) 2013-01-22
EP1781789A2 (en) 2007-05-09
US9005945B2 (en) 2015-04-14
US20090130069A1 (en) 2009-05-21
PL1781789T3 (pl) 2011-12-30
KR20070032786A (ko) 2007-03-22
CA2569304C (en) 2014-08-12
US20190070312A1 (en) 2019-03-07
CN101010428A (zh) 2007-08-01
WO2005123912A3 (en) 2006-05-04
US20150231275A1 (en) 2015-08-20
US8642311B2 (en) 2014-02-04
KR101337210B1 (ko) 2013-12-06
US20130028876A1 (en) 2013-01-31
EP1781789B1 (en) 2011-08-17
IL179660A0 (en) 2007-05-15
CY2016054I1 (el) 2017-07-12
IL179660A (en) 2012-12-31
NL300856I2 (lt) 2017-04-20
CY2016054I2 (el) 2017-07-12
US10155052B2 (en) 2018-12-18
HUS1600064I1 (hu) 2017-02-28
LTC1781789I2 (lt) 2018-10-10
GB0413702D0 (en) 2004-07-21

Similar Documents

Publication Publication Date Title
LTPA2016047I1 (lt) Timidinkinazė
DE602006015405D1 (de) Inkrementelle Assoziation von Metadaten zu Produktionsdaten
DK1966195T3 (da) 5-arylisoxazoliner til bekæmpelse af hvirvelløse skadedyr
GT200500272A (es) 2-anilinopirimidinas sustituidas como inhibidores de la quinasa del ciclo celular o del receptor de la tirosina quinasa, su preparacion y su uso como medicamentos
ATE430589T1 (de) Wasserbehandlung zur kontrolle von biobewuchs mittels stabilisierter bromlösungen
ATE538127T1 (de) 6-disubstituierte bicyclische nukleinsäureanaloga
CR8385A (es) Pirimidinas sustituidas con sulfoximina como inhibidores de cdk y/o vegf, su preparacion y sus usos como medicamento
ATE315585T1 (de) Multispezifisches reagenz zur selektiven stimulierung von zelloberflächenrezeptoren
CY1111486T1 (el) Μιμητικα αντισωματα (mimetibodies) δεσμευμενα με υποδοχεα μελανοκορτινης, συνθεσεις, μεθοδοι και χρησεις
NO20100724L (no) Ledende sementformulering og anvendelse av denne i en bronn
ATE423345T1 (de) Prozessor mit verschiedenartigen steuerwerken für gemeinsam genutzte ressourcen
ATE536360T1 (de) Neues nukleinsäuretransfersystem
ATE438726T1 (de) Modulation der anzahl von pflanzenzellen
BRPI0716763A2 (pt) grande de chapa delgada énica com bulbo reforÇado
ITTO20050108A1 (it) Trasmissione idrostatica a variazione continua.
DK2176466T3 (da) Byggesæt til fremstilling af brolægningsflader
ATE544599T1 (de) Fluidzufuhrsystem
ATE543828T1 (de) Heteropolynukleotid-duplexe mit purin-purin- paarung
ATE501160T1 (de) Neues markiertes oligonukleotid
DK2254950T3 (da) 1,3-thiazolyl-azo-farvestoffer, deres frembringelse og anvendelse
TR200704119A2 (tr) Bir toprak işleme makinası
TW200833903A (en) Construction method of combining geogrid rack and concrete
ATE443929T1 (de) Enzymatische brennstoffzelle
FR2853906B1 (fr) N-desoxyribosyltransferases de lactobacilles, sequences nucleotidiques correspondantes et leurs applications
DK1478664T3 (da) Vævsspecifik ekspression